Janux Therapeutics, Inc. Operating Lease, Lease Income, Lease Payments
Janux Therapeutics, Inc. (JANX) reported Operating Lease, Lease Income, Lease Payments of $1.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:OperatingLeaseLeaseIncomeLeasePayments · last filed 2026-08-06
- Janux Therapeutics, Inc. operating lease, lease income, lease payments for the quarter ending 2026-06-30 was $1.00M, a 11.11% increase year-over-year.
- Janux Therapeutics, Inc. operating lease, lease income, lease payments for the quarter ending 2026-03-31 was $1.00M, a 11.11% increase year-over-year.
- Janux Therapeutics, Inc. operating lease, lease income, lease payments for the quarter ending 2025-12-31 was $1.00M, a 11.11% increase year-over-year.
- Janux Therapeutics, Inc. operating lease, lease income, lease payments for the quarter ending 2025-09-30 was $900.00K, a 0.00% change year-over-year.
- Janux Therapeutics, Inc. operating lease, lease income, lease payments for fiscal 2025 was $3.60M, a 5.88% increase from fiscal 2024.
- Janux Therapeutics, Inc. operating lease, lease income, lease payments for fiscal 2024 was $3.40M, a 21.43% increase from fiscal 2023.
- Janux Therapeutics, Inc. operating lease, lease income, lease payments for fiscal 2023 was $2.80M, a 1300.00% increase from fiscal 2022.
- Janux Therapeutics, Inc. operating lease, lease income, lease payments for fiscal 2022 was $200.00K, a 33.33% decline from fiscal 2021.
| Period end | Operating Lease, Lease Income, Lease Payments 3 month | Operating Lease, Lease Income, Lease Payments 6 month | Operating Lease, Lease Income, Lease Payments 9 month | Operating Lease, Lease Income, Lease Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00M 10-Q · filed 2026-08-06 | $2.00M 10-Q · filed 2026-08-06 | $3.00M derived: sum of 3 quarters · filed 2026-08-06 | $3.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.00M 10-Q · filed 2026-05-07 | $2.00M derived: sum of 2 quarters · filed 2026-05-07 | $2.90M derived: sum of 3 quarters · filed 2026-05-07 | $3.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.90M derived: sum of 2 quarters · filed 2026-02-26 | $2.80M derived: sum of 3 quarters · filed 2026-08-06 | $3.60M 10-K · filed 2026-02-26 |
| 2025-09-30 | $900.00K 10-Q · filed 2025-11-06 | $1.80M derived: sum of 2 quarters · filed 2026-08-06 | $2.60M 10-Q · filed 2025-11-06 | $3.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $900.00K 10-Q · filed 2026-08-06 | $1.70M 10-Q · filed 2026-08-06 | $2.70M derived: sum of 3 quarters · filed 2026-08-06 | $3.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $900.00K 10-Q · filed 2026-05-07 | $1.80M derived: sum of 2 quarters · filed 2026-05-07 | $2.70M derived: sum of 3 quarters · filed 2026-05-07 | $3.50M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.80M derived: sum of 2 quarters · filed 2026-02-26 | $2.60M derived: sum of 3 quarters · filed 2026-02-26 | $3.40M 10-K · filed 2026-02-26 |
| 2024-09-30 | $900.00K 10-Q · filed 2025-11-06 | $1.70M derived: sum of 2 quarters · filed 2025-11-06 | $2.50M 10-Q · filed 2025-11-06 | $3.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $800.00K 10-Q · filed 2025-08-07 | $1.70M 10-Q · filed 2025-08-07 | $2.50M derived: sum of 3 quarters · filed 2026-02-26 | $3.30M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $800.00K 10-Q · filed 2025-05-08 | $1.70M derived: sum of 2 quarters · filed 2026-02-26 | $2.50M derived: sum of 3 quarters · filed 2026-02-26 | $3.30M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.70M derived: sum of 2 quarters · filed 2026-02-26 | $2.50M derived: sum of 3 quarters · filed 2026-02-26 | $2.80M 10-K · filed 2026-02-26 |
| 2023-09-30 | $800.00K 10-Q · filed 2024-11-06 | $1.60M derived: sum of 2 quarters · filed 2024-11-06 | $1.90M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $800.00K 10-Q · filed 2024-08-07 | $1.10M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $300.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $200.00K 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $300.00K 10-K · filed 2023-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |